A University of Exeter-led study has identified a previously under-recognized way that Candida auris can survive antifungal treatment. Published in Nature Communications on October 15, 2026, the research reports that some cells produced multiple copies of their entire genome after exposure to antifungal drugs. The team found two surviving cell populations, according to the University of Exeter. Some grew slowly, while others multiplied more quickly and carried varied mutations in CRZ1, a gene involved in cell-wall processes. Tests indicated that the fast-growing mutants’ cell walls were not affected by the drugs in the same way as expected. The researchers describe the combination of different survival strategies as “bet-hedging.” The discovery followed an unexpected observation during laboratory testing: cells continued to grow after plates were left incubating beyond the planned test period. Researchers had been investigating why the fungus appeared to survive drugs even when laboratory tests suggested it was not resistant. The study’s title notes that the reported mechanisms do not depend on variants in FKS1 or FKS2, genes associated with antifungal resistance. Candida auris has been reported in more than 60 countries, and the World Health Organization lists it among its critical priority fungal pathogens, according to the source. Researchers say the findings could guide investigation of approaches such as combining antifungal drugs; Exeter’s Fungi-CARE programme is examining that area with City St George’s colleagues. For mushroom readers, the work highlights how much fungal survival strategies can vary, even within a single species. The study was led by researchers at the University of Exeter and City St George’s, University of London.